The Efficacy of Intranasal Fluticasone Propionate in the Relief of Ocular Symptoms Associated with Seasonal Allergic Rhinitis

Allergy and Asthma Proceedings

Volumn 24, Issue 5, 2003, Pages 331-337

  DeWester, Jeffrey ^a   Philpot, Edward E ^b   Westlund, Ronald E ^b   Cook, Cindy K ^b   Rickard, Kathleen A ^b  

^a De Wester Family Medicine Treatment and Research   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DECONGESTIVE AGENT; EYE DROPS; FLUTICASONE PROPIONATE; PLACEBO;

ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EPISTAXIS; EYE IRRITATION; FEMALE; HEADACHE; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MALE; PRURITUS; RETROSPECTIVE STUDY; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRANASAL; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; DOUBLE-BLIND METHOD; EYE DISEASES; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0242521710     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Nathan RA, Meltzer EO, Selner JC, et al. Prevalence of allergic rhinitis in the US. J Allergy Clin Immunol 99:808-814, 1997.
2. Food and Drug Administration. Allergic rhinitis: clinical development programs for drug products. Food and Drug Administration draft guidance for industry, April 2000.
3. Lebel B, Bousquet J, Morel A, et al. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 88:869-877, 1988.
4. Dykewicz MS, Fineman S (Eds). Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
5. Gawchik SM, and Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis. Am J Manag Care 3:1052-1058, 1997.
6. Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 17:252-263, 1995.
7. Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy 73:147-153, 1994.
8. Scadding GK, Lund VJ, Holmstrom M, et al. Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial allergic rhinitis. Rhinol Suppl 11:37-43, 1991.
9. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 317:1624-1629, 1998.
10. Stempel DA, and Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Manag Care 4:89-96, 1998.
11. Howland WC. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy 26:18-22, 1996.
12. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 84:25-29, 1990.
13. Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 47:118-125, 1998.
14. LaForce CF, Dockhorn RJ, Findlay SR, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 38:145-152, 1994.
15. Nathan RA, Bronsky EA, Fireman P, et al. A once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 67:332-338, 1991.
16. Banov CH, Woechler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 73:240-246, 1994.
17. Product Information Flonase (fluticasone propionate) Nasal Spray. 2000.
18. Bronsky EA, Dockhorn RJ, Meltzer EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 97:915-921, 1996.
19. Lemanske R, Dunn K, Galant S, et al. Fluticasone propionate aqueous nasal spray is more effective than astemizole in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 93:165, 1994 (Abs).
20. van Bavel J, Ratner PH, Nayak AS, et al. Ocular efficacy and clinician overall evaluation of intranasal fluticasone propionate (FP) versus loratadine (LOR) in seasonal allergic rhinitis (SAR). Ann Allergy 78:128, 1997 (Abs).
21. Alvarado-Valdes CA, Blomgren J, Weiler D, et al. The effect of fluticasone propionate aqueous nasal spray on eosinophils and cytokines in nasal secretions of patients with ragweed allergic rhinitis. Clin Ther 19:273-281, 1997.
22. Stricker WE, Nathan RA, Winder JA, et al. Fluticasone propionate aqueous nasal spray (FP) and loratadine (LOR), alone and in combination, in the treatment of fall seasonal allergic rhinitis (SAR). Ann Allergy 80:115, 1998 (Abs).
23. van Bavel J, Findlay SR, Hampel FC, et al. Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis. Arch Intern Med 154:2699-2704, 1994.
24. Linder A. Symptom scores as measurements of the severity of rhinitis. Clin Allergy 18:29-37, 1988.
25. Bryson HM, and Faulds D. Intranasal fluticasone propionate: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 43:760-775, 1992.
26. Undem BJ, Kajekar R, Hunter DD, et al. Neural integration and allergic disease. J Allergy Clin Immunol 106:S213-S220, 2000.
27. Baraniuk JN, Silver PB, Kaliner MA, et al. Perennial rhinitis subjects have altered vascular, glandular, and neural responses to bradykinin nasal provocation. Int Arch Allergy Immunol 103:202-208, 1994.
28. Riccio MM, and Proud D. Evidence that enhanced nasal reactivity to bradykinin in symptomatic allergic individuals is mediated by neural reflexes. J Allergy Clin Immunol 97:1252-1263, 1996.
29. Juniper EF, Kline PA, Hargreave FE, et al. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 83:627-633, 1989.
30. Pichler WJ, Klint T, Blaser M, et al. Clinical comparison of systemic methylprednisolone acetate versus topical budesonide in patients with seasonal allergic rhinitis. Allergy 43:87-92, 1988.
31. Bjernum P, and Illum P. Treatment of seasonal allergic rhinitis with budesonide and disodium cromoglycate. Allergy 40:65-59, 1985.
32. Lindqvist N, Andersson M, Bende M, et al. The clinical efficacy of budesonide in hay fever treatment is dependent on topical nasal application. Clin Exp Allergy 19:71-76, 1989.
33. Product Information Rhinocort (budesonide) Aqueous Nasal Spray. 2001.
34. Daley-Yates PT, and McAllister T. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulation. Br J Clin Pharmacol 51:103-105, 2001.
35. van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 91:1146-1154, 1993.
36. Derby L, and Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 105:912-916, 2000.